Celldex Therapeutics
CLDX
182 hedge funds and large institutions have $2.58B invested in Celldex Therapeutics in 2024 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 81 increasing their positions, 49 reducing their positions, and 36 closing their positions.
65% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 49
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
2% less ownership
Funds ownership: 107.59% → 105.59% (-2%)
8% less funds holding
Funds holding: 197 → 182 (-15)
11% less capital invested
Capital invested by funds: $2.91B → $2.58B (-$333M)
33% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 36
80% less call options, than puts
Call options by funds: $3.39M | Put options by funds: $17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$32.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$24.7M |
| 3 |
CC
Commodore Capital
New York
|
+$21.1M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$18.4M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$18.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$71.6M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$27.3M |
| 3 |
State Street
Boston,
Massachusetts
|
-$12.1M |
| 4 |
AG
Artal Group
Luxembourg
|
-$10.6M |
| 5 |
Renaissance Technologies
New York
|
-$10.2M |
CLDX Hedge Fund Activity: Q2 2024 in Review
182 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q2 2024, worth a combined $2.58B — down 11% from $2.91B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of CLDX and 24 opened new positions — a net loss of 12 holders — while 49 trimmed existing stakes and 81 added.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $32.1M. The largest seller was Fidelity Investments, cutting an estimated $71.6M.
- 182 institutional investors held Celldex Therapeutics (CLDX) as of Q2 2024, down from 197 in Q1 2024.
- Funds reported $2.58B of Celldex Therapeutics stock for Q2 2024, down 11% quarter-over-quarter.
- 24 funds opened new Celldex Therapeutics positions in Q2 2024 and 36 closed out, a net change of -12 holders.
- The largest Celldex Therapeutics buyer in Q2 2024 was Novo Holdings A/S, an estimated $32.1M added.
- The largest Celldex Therapeutics seller in Q2 2024 was Fidelity Investments, an estimated $71.6M sold.
Based on aggregated 13F filings for Q2 2024.